Summary
The accumulation rates of 3,4′-dihydroxyphenyl-alanine (DOPA) and 5-hydroxytrypthophan (5-HTP) after inhibition of aromatic amino acid decarboxylase (AADC) by 3-hydroxybenzylhydrazine (NSD 1015) or 1-(dl-seryl)-2(2,3,4-trihydroxybenzyl)hydrazine (Ro 4-4602) have widely been used as measurements of the in vivo synthesis rates of monoamines. However, the values of dopamine (DA) turnover in rat striatum obtained using these drugs are much lower than values obtained by other methods. This discrepancy prompted us to further investigate the AADC inhibitor 1-(3-hydroxybenzyl)-1-methylhydrazine (NSD 1034) which earlier has been shown to give a DOPA accumulation rate in the striatum of the same magnitude as other measures of DA turnover. NSD 1034 was found to give a more than twofold higher DOPA accumulation rate than NSD 1015, NSD 1024, NSD 1039, NSD 1055 and Ro 4-4602 in the striatum. Also, in the limbic region and the hemispheres, but not in the substantia nigra, the DOPA accumulation was higher after NSD 1034 than after NSD 1015, but the difference was less pronounced. There was, however, no difference in 5-HTP accumulation between the drugs in any of the brain parts investigated. Although the DOPA accumulation rates are higher after NSD 1034 than after NSD 1015, the NSD 1015-induced DOPA accumulation seems to be more sensitive to changes in dopamine receptor occupancy. The different DOPA accumulation rates obtained with NSD 1015 and NSD 1034 are not due to differences in MAO inhibition, to interference with classical DA receptors, or to different degrees of AADC inhibition, but to an ability of NSD 1034 to stimulate DA synthesis. In addition, under certain conditions NSD 1034 also has a DA releasing action, like amphetamine. It is proposed that NSD 1034 and amphetamine stimulate DA synthesis and release by a common mechanism. The low value of DA synthesis rate, obtained when measured as DOPA accumulation after NSD 1015, is due to a substantial efflux of DOPA from the brain. The efflux of DOPA is equally large after NSD 1034 but the loss is compensated for by an increase in DOPA synthesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén N-E, Bédard P, Fuxe K, Ungerstedt U (1972) Early and selective increase in brain dopamine levels after axotomy. Experentia 28:300–301
Andén N-E, Grabowska-Andén M, Liljenberg B (1983) Demonstrations of autoreceptors on dopamine neurons in different brain regions of rats treated with gammabutyrolactone. J Neural Trans 58:143–152
Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxidetrihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138:360–375
Bowsher RR, Henry DP (1985) Aromatic l-amino acid decarboxylase. Biochemistry and functional significance. In: Boulton AA, Baker GB, Yu PH (eds) Neuromethods, Series 1: Neurochemistry. Humana Press, Clifton, New Jersey, pp 3378
Brodie BB, Kuntzman R, Hirsch CW, Costa E (1962) Effects of decarboxylase inhibition of the biosynthesis of brain monoamines. Life Sci 3:81–84
Brown F, Campbell W, Mitchell PJ, Randall K (1985) Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis. Br J Pharmacol 84:853–860
Burkard WP, Gey KF, Pletcher A (1962) A new inhibitor of decarboxylase of aromatic amino acids. Experentia 18:411–412
Carlsson A (1964) Functional significance of drug-induced changes in brain monoamine levels. In: Himwich HE, Himwich WA (eds) Progress in brain research, vol 8 Elsevier Publishing Company Amsterdam London New York pp 9–27
Carlsson A (1974) Antipsychotic drugs and catecholamine synapses. J Psychiat Res 11:57–64
Carlsson A, Lindqvist M (1973a) In-vivo measurements of tryptophan and tyrosine hydroxylase activities in mouse brain. J Neural Transm 34:79–91
Carlsson A, Lindqvist M (1973b) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437–440
Carlsson A, Davis JN, Kehr W, Lindqvist M, Atack CV (1972) Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedberg's Arch Pharmacol 275:153–168
Carlsson A, Kehr W, Lindqvist M (1974) Short-term control of tyrosine hydroxylase. In: Usdin E (ed) Neuropsychopharmacology of monoamines and their regulatory enzymes. Raven Press, New York, pp 135–142
Carlsson A, Kehr W, Lindqvist M (1977) Agonist-antagonist interactions on dopamine receptors in brain, as reflected in the rates of tyrosine and tryptophan hydroxylation. J Neural Transm 40:99–113
Carlsson M, Eriksson E (1986) A central serotonin receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, has different effects on prolactin secretion in male and female rats. Acta Pharmacol Toxicol 58:297–302
Clark D, Engberg G, Pileblad E, Svensson TH, Carlsson A, Freeman AS, Bunney BS (1985) An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn-Schmiedeberg's Arch Pharmacol 329:344–355
Drain DJ, Horlington M, Lazare R, Poulter GA (1962) The effect of α-methyl DOPA and some other decarboxylase inhibitors on brain 5-hydroxytryptamine. Life Sci 3:93–97
Felice LJ, Felice JD, Kissinger PT (1978) Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neurochem 31:1461–1465
Gerber R, Altar CA, Liebman JM (1988) Rotational behaviour induced by 8-hydroxy-DPAT, a putative 5HT-1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology 94:178–182
Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons. 1. Identification and characterization. Neuroscience 10:301–315
Hansson E, Fleming RM, Clark WG (1964) Effect of some benzylhydrazines and benzyloxyamines on DOPA and 5-hydroxytryptophan decarboxylase in vivo. Int J Neuropharmacol 3:177–188
Harris JE, Baldessarini RJ, Roth RH (1975) Amphetamine-induced inhibition of tyrosine hydroxylation in homogenates of rat corpus striatum. Neuropharmacology 14:457–471
Hassler R, Bak IJ (1969) Unbalanced ratios of striatal dopamine and serotonin after experimental interruption of strionigral connections in rat. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson's disease. Livingstone, Edinburgh London, pp 27–29
Hempel K, Männl HFK (1966) The conversion of H3-tyrosine to H3-DOPA in the adrenal glands under in vivo conditions. Experentia 22:689–690
Hempel K, Männl HFK (1967) Über die Bildung von H3-DOPA aus H3-Tyrosine und die Bestimmung der DOPA-Neubildungsrate in der Nebenniere des Huhnes und der Katze unter in vivo-Bedingungen. Naunyn-Schmiedebergs Arch Pharmacol 257:391–408
Hjorth S, Carlsson A (1988) In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH 23390. J Neural Transm 72:83–97
Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: A new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4:966–977
Juorio AV (1983) The effects of some decarboxylase inhibitors on striatal tyramines in the mouse. Neuropharmacology 22:71–73
Kehr W (1976) 3-Methoxytyramine as an indicator of impulse-induced dopamine release in rat brain in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 293:209–215
Kehr W, Carlsson A, Lindqvist M, Magnusson T, Atack C (1972) Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 24:744–747
Kehr W, Speckenbach W, Zimmermann R (1977) Interaction of haloperidol and γ-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat brain. J Neural Transm 40:129–147
Kehr W, Debus G, Neumeister R (1985) Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. J Neural Transm 63:1–12
Kilts CD, Anderson CM, Ely TD, Nishita JK (1987) Absence of synthesis-modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J Neurosci 7:3961–3975
Korf J (1981) Turnover of neurotransmitters in the brain: an introduction. In: Pycock CJ, Taberner PV (eds) Central neutrotransmitter turnover. Croom Helm Ltd, London, pp 119
Kuczenski R (1975) Effects of catecholamine releasing agents on synaptosomal dopamine biosynthesis: multiple pools of dopamine or multiple forms of tyrosine hydroxylase. Neuropharmacology 14:1–110
Kuczenski RT, Mandell AJ (1972) Regulatory properties of soluble and particulate rat brain tyrosine hydroxylase. J Biol Chem 247:3114–3122
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Magnusson O, Nilsson LB, Westerlund D (1980) Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J Chromatogr 221:237–247
Magnusson O, Mohringe B, Fowler CJ (1987) Comparison of the effects of dopamine D 1 and D 2 receptor antagonists on rat striatal, limbic and nigral dopamine synthesis and utilization. J Neural Transm 69:163–177
Markwell MAK, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206–210
Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine hydroxylase. The initital step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917
Nissbrandt H, Carlsson A (1987) Turnover of dopamine and dopamine metabolites in rat brain: comparison between striatum and substantia nigra. J Neurochem 49:959–967
Pearl RG, Seiden LS (1979) d-Amphetamine-induced increase in catecholamine synthesis in the corpus striatum of the rat: persistence of the effect after tolerance. J Neural Transm 44:21–38
Peringer E, Jenner P, Donaldson IM, Marsden CD (1976) Metoclopramide and dopamine receptor blockade. Neuropharmacology 15:463–469
Roth RH, Walters JR, Aghajanian GK (1973) Effect of impulse flow on the release and synthesis of dopamine in the rat striatum. In: Usdin E, Snyder SH (eds) Frontiers in catecholamine research. Pergamon Press, New York, pp 567–574
Schwabe U, Miyake M, Ohga Y, Daly JW (1976) 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′, 5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12:900–910
Simonovic M, Gudelsky GA, Meltzer HY (1984) Effect of 8-hydroxy-2-(di-n-propylamino) tetralin on rat prolactin secretion. J Neural Transm 59:143–149
Uretsky NJ, Snodgrass R (1977) Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices. J Pharmacol Exp Ther 202:565–580
Uretsky NJ, Kamal L, Snodgrass R (1979) Effect of divalent cations on the amphetamine-induced stimulation of [3H] catechol synthesis in the striatum. J Neurochem 32:951–960
Walters JR, Roth RH (1974) Dopaminergic neurons: drug-induced antagonism of the increase in tyrosine hydroxylase activity by cessation of impulse flow. J Pharmacol Exp Ther 191:82–91
Westerink BHC (1979) Effect of drugs on the formation of 3-methoxytyramine, a dopamine metabolite, in the substantia nigra, striatum, nucleus accumbens and tuberculum olfactorium of the rat. J Pharm Pharmacol 31:94–99
Westerink BHC, Spaan SJ (1982) On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 38:680–686
Author information
Authors and Affiliations
Additional information
Send offprint request to Hans Nissbrandt at the above address
Rights and permissions
About this article
Cite this article
Nissbrandt, H., Engberg, G., Wikström, H. et al. NSD 1034: An amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 338, 148–161 (1988). https://doi.org/10.1007/BF00174863
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00174863